WATERTOWN, Mass., June 12, 2025 - Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced positive updates across its clinical programs at the European Hematology Association (EHA) 2025 Annual Congress in Milan, Italy. The company presented data from various studies, including the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria $(EPP.UK)$, showcasing long-term efficacy and safety. Additionally, Disc Medicine shared durability data from a Phase 1b study of DISC-0974 in anemia of myelofibrosis and updates from DISC-3405 studies in healthy volunteers. A confirmatory clinical trial, APOLLO, has been initiated for bitopertin in adults and adolescents with EPP. Disc Medicine plans to submit a New Drug Application (NDA) for bitopertin in the second half of 2025. The company will host a corporate update conference call on June 16, 2025, to discuss these developments. All investigational agents mentioned, including bitopertin, DISC-0974, and DISC-3405, are not yet approved for therapeutic use globally.